Last reviewed · How we verify
NCT00262717
Can Resistance Enhance Selection of Treatment? (CREST)
NA trial testing Blood test: genotype testing in HIV Infection in 338 participants. Completed in 31 July 2006.
30 January 2006
Quick facts
| Lead sponsor | Kirby Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 338 |
| Start date | 1 March 2001 |
| Primary completion | 30 January 2006 |
| Estimated completion | 31 July 2006 |
| Sites | 19 locations across Australia |
Drugs / interventions tested
- Blood test: genotype testing
Conditions studied
- HIV Infection — all drugs for HIV Infection →
Sponsor
Kirby Institute
Who can join
18 and older, any sex, with HIV Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare two commercially available platforms for assessment of HIV drug resistance to determine which provides superior virological results. We hypothesise that one test will be significantly superior to the other.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00262717
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV Infection
Currently open trials in the same condition.
- NCT06900829 — #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-i · NA · recruiting
- NCT06908252 — MAPS PrEP Van Study · Phase 4 · recruiting
- NCT07042945 — MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) · Phase 1 · recruiting
- NCT06716450 — Multiplo Tp/HIV Self-Test · NA · recruiting
- NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting
Other Kirby Institute trials
Trials by the same sponsor.
- NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
- NCT06220370 — PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised. · not yet recruiting
- NCT05415267 — Immunosuppression and COVID-19 Boosters · Phase 3 · recruiting
- NCT05144776 — Evaluation of Hepatitis B Virus (HBV) DNA Test As Point of Care Tool · completed
- NCT04014179 — Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00262717 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kirby Institute
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00262717.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing